(3S)-3-[[2-[[(2S)-2-[[4-[[(8R,9S,13S,14S,17S)-3-[2-[[(2S)-1-[[2-[[(2S)-3-carboxy-1-[[(1S)-1-carboxy-2-phenylethyl]amino]-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-2-oxoethoxy]-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-17-yl]oxy]-4-oxobutanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]acetyl]amino]-4-[[(1S)-1-carboxy-2-phenylethyl]amino]-4-oxobutanoic acid | 1166993-76-5

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (3S)-3-[[2-[[(2S)-2-[[4-[[(8R,9S,13S,14S,17S)-3-[2-[[(2S)-1-[[2-[[(2S)-3-carboxy-1-[[(1S)-1-carboxy-2-phenylethyl]amino]-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-2-oxoethoxy]-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-17-yl]oxy]-4-oxobutanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]acetyl]amino]-4-[[(1S)-1-carboxy-2-phenylethyl]amino]-4-oxobutanoic acid
• CAS: 1166993-76-5
• 化学式: C₆₆H₈₈N₁₄O₁₉
• 分子量: 1381.51
• InChiKey: VDXJDRUSZRHJQJ-ANBONMNPSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0
• 重原子数：
  99
• 可旋转键数：
  40
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  546
• 氢给体数：
  16
• 氢受体数：
  21

反应信息

• 作为产物：
  描述：

  在 palladium 10% on activated carbon 、 氢气 作用下， 以 甲醇 、 水 为溶剂， 反应 20.0h， 以88%的产率得到(3S)-3-[[2-[[(2S)-2-[[4-[[(8R,9S,13S,14S,17S)-3-[2-[[(2S)-1-[[2-[[(2S)-3-carboxy-1-[[(1S)-1-carboxy-2-phenylethyl]amino]-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-2-oxoethoxy]-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-17-yl]oxy]-4-oxobutanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]acetyl]amino]-4-[[(1S)-1-carboxy-2-phenylethyl]amino]-4-oxobutanoic acid
  参考文献：
  名称：

  3D QSAR of novel estrogen–RGD peptide conjugates: Getting insight into structural dependence of anti-osteoporosis activity and side effect of estrogen in ERT

  摘要：

  To explore the structural dependence of the oral potency and side effect of estrogen-RGD peptide conjugates, here six novel conjugates were prepared via introducing RGD-tetrapeptides into both 3- and 17-positions of estradiol, and introducing RGD-octapeptides into 3-position of estrone. In an ovariectomized mouse model they exhibited higher anti-osteoporosis activity and lower side effect than estrogen. For 3D QSAR analysis the anti-osteoporosis activities of nine known conjugates estrogen-RGD tetrapeptide conjugates were also provided. Using Cerius(2) module their 3D QSAR analysis was performed, four equations with high r(2) values were established, and the structural dependence of the oral potency and side effect of them was elucidated. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2009.03.057

文献信息

• 3D QSAR of novel estrogen–RGD peptide conjugates: Getting insight into structural dependence of anti-osteoporosis activity and side effect of estrogen in ERT
  作者：Ming Zhao、Jiangyuan Liu、Xiaoyi Zhang、Li Peng、Chunyu Li、Shiqi Peng

  DOI：10.1016/j.bmc.2009.03.057

  日期：2009.5

  To explore the structural dependence of the oral potency and side effect of estrogen-RGD peptide conjugates, here six novel conjugates were prepared via introducing RGD-tetrapeptides into both 3- and 17-positions of estradiol, and introducing RGD-octapeptides into 3-position of estrone. In an ovariectomized mouse model they exhibited higher anti-osteoporosis activity and lower side effect than estrogen. For 3D QSAR analysis the anti-osteoporosis activities of nine known conjugates estrogen-RGD tetrapeptide conjugates were also provided. Using Cerius(2) module their 3D QSAR analysis was performed, four equations with high r(2) values were established, and the structural dependence of the oral potency and side effect of them was elucidated. (C) 2009 Elsevier Ltd. All rights reserved.